On 19 November 2018, orphan designation (EU/3/18/2087) was granted by the European Commission to Consejo Superior de Investigaciones Cientificas, Spain, for etamsylate for the treatment of hereditary haemorrhagic telangiectasia.
The sponsorship was transferred to Dobecure S.L., Spain in June 2020.
|Disease / condition||
Treatment of hereditary haemorrhagic telangiectasia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.